348 related articles for article (PubMed ID: 37535161)
1. Optimized risk stratification strategy for glioma patients based on the feature genes of poor immune cell infiltration patterns.
Wan HT; Su ZJ; Guo ZS; Wen P; Hong XY
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13855-13874. PubMed ID: 37535161
[TBL] [Abstract][Full Text] [Related]
2. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
3. Illustrating the biological functions and diagnostic value of transmembrane protein family members in glioma.
Zhang Y; Zhang W; Yuan Q; Hong W; Yin P; Shen T; Fang L; Jiang J; Shi F; Chen W
Front Oncol; 2023; 13():1145676. PubMed ID: 37064154
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the GPAT/AGPAT gene family in hepatocellular carcinoma and its role in the tumor immune microenvironment.
Wen P; Wang R; Xing Y; Ouyang W; Yuan Y; Zhang S; Liu Y; Peng Z
Front Immunol; 2023; 14():1026669. PubMed ID: 36845084
[TBL] [Abstract][Full Text] [Related]
5. Characterization of DNA Damage Repair Related Signature and Molecular Feature in Low-Grade Gliomas to Aid Chemotherapy and Drug Discovery.
Yin X; Li M; He Z
Front Biosci (Landmark Ed); 2023 Oct; 28(10):234. PubMed ID: 37919061
[TBL] [Abstract][Full Text] [Related]
6. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
8. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
9. Integrated clustering signature of genomic heterogeneity, stemness and tumor microenvironment predicts glioma prognosis and immunotherapy response.
Wu Y; Mao M; Wang LJ
Aging (Albany NY); 2023 Sep; 15(17):9086-9104. PubMed ID: 37698534
[TBL] [Abstract][Full Text] [Related]
10. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
11. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract][Full Text] [Related]
12. The study of an anoikis-related signature to predict glioma prognosis and immune infiltration.
Zhang D; Wang Y; Zhou H; Han X; Hou L; Lv Z; Xue X
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12659-12676. PubMed ID: 37450027
[TBL] [Abstract][Full Text] [Related]
13. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
14. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
15. Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma.
Zhang Y; Zhang C; Yang Y; Wang G; Wang Z; Liu J; Zhang L; Yu Y
Front Cell Dev Biol; 2022; 10():862493. PubMed ID: 35547808
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
17. Identification of heterogeneous subtypes and a prognostic model for gliomas based on mitochondrial dysfunction and oxidative stress-related genes.
Li J; Wang S; Chi X; He Q; Tao C; Ding Y; Wang J; Zhao J; Wang W
Front Immunol; 2023; 14():1183475. PubMed ID: 37334354
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
19. Integrative Analysis of Inflammatory Response-Related Gene for Predicting Prognosis and Immunotherapy in Glioma.
Zhao Z; Zheng B; Zheng J; Zhang Y; Jiang C; Nie C; Jiang X; Yao D; Zhao H
J Mol Neurosci; 2023 Aug; 73(7-8):608-627. PubMed ID: 37488455
[TBL] [Abstract][Full Text] [Related]
20. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
Xu S; Wang Z; Ye J; Mei S; Zhang J
Front Oncol; 2021; 11():729103. PubMed ID: 34568059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
